U.S. development Phase success rates for rare and common disease drugs 2011-2020
This statistic shows the probability of success for new rare disease and high prevalence disease drugs in the U.S. through the various stages of development, from January 1, 2011, to November 30, 2020. It was found that while the probability that a new drug for a chronic high prevalence disease makes it from phase I to approval was only 5.9 percent, while it was 17 percent for rare disease drugs.
